Table 2.
The oncologic outcomes of SLNM in high-risk EC.
| Author | Year of publication | Country | Study type | Time period | Patient group (N) | Histology | LN positive rate | p value | DFS | p value | OS | p value | Distant recurrence rate | p value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schiavone et al. (114) | 2016 | USA | retro | 1998.01-2014.08 | SLN-A(48) | USM | 22.90% | p=0.4 | 23m(2y) | p=0.7 | NA | 70% | NA | |
| LAD(88) | 21.59% | 23.2m | NA | 74% | ||||||||||
| Ducie et al. (107) | 2017 | USA | retro | SLN (2006–2013) | SLN-A(120) | EEC: any grade, MI>50%; USC/CC, any MI. | 21.70% | p=0.68 | NA | NA | NA | |||
| LAD (2004–2008) | SLAD(103) | 19.40% | NA | NA | NA | |||||||||
| Schiavone et al. (115) | 2017 | USA | retro | 2005.01-2015.07 | SLN-A(153) | USC | 31% | p=0.3 | 77% | p=0.3 | NA | 15.03% | NA | |
| LAD(95) | 38% | 71% | NA | 23.16% | ||||||||||
| Baiocchi et al. (106) | 2017 | Spain | retro | SLN (2007.06-2017.02) | SLN+LAD(75) | EEC(G3), CC, USC, CSM, DM, LVSI | 26.70% | p=0.02 | NA | NA | NA | |||
| LAD (2012.11-2017.02) | LAD(161) | 14.30% | NA | NA | NA | |||||||||
| Buda et al. (111) | 2018 | Italy, Switzerland | retro | NA | SLN-A(66) | High-intermediate and high-risk | 27.30% | p=0.297 | 79.20% | p=0.831 | NA | 0 | NA | |
| SLN+SLAD(105) | 32.40% | 81.60% | NA | 0.95% | ||||||||||
| Buda et al. (116) | 2018 | Italy | retro | 2010.10-2014.02 | SLN(61) | High-intermediate and high-risk | 16.70% | p=0.002 | HR: 0.92(3y) | p=0.646 | HR: 0.92(3y) | p=0.675 | NA | |
| LAD(139) | 7.30% | NA | ||||||||||||
| Schlappe et al. (117) | 2018 | USA | SLN (2005–2013) | SLN-A(82) | DM EEC | 33.30% | p=0.005 | adjusted HR:0.87 | NA | adjusted HR:2.54 | NA | 20.80% | NA | |
| LND (2004–2008) | LAD(94) | 14.80% | 14.90% | |||||||||||
| Basaran et al. (118) | 2020 | USA | retro | 1996.01-2017.12 | SLN alone(79) | USC | 26.50% | p=0.6 | 58.8%(2y) | p=0.478 | 89.1%(2y) | p=0.9 | 36.7%※ | p=0.524 |
| LND without SLN (166) | 29.50% | 64.9%(2y) | 83.9%(2y) | 40.9%※ | ||||||||||
| Schlappe et al. (119) | 2020 | USA | retro | 2006- 2013 | SLN(118) | USC/CC with any MI | 21.70% | p=0.83 | 68.9%(3y) | p=0.32 | 87.9%(3y) | p=0.06 | NA | |
| 2004- 2008 | LND(96) | 20.50% | 80.3%(3y) | 76.8%(3y) | ||||||||||
| Nasioudis et al. (120) | 2020 | USA | retro | 2012-2015 | SLN(460) | EEC(G3) and non-EEC | 10.5% | p=0.10 | NA | 84.3%(3y) | p=0.86 | NA | ||
| LND(920) | 13.30% | NA | NA | 86.8%(3y) | ||||||||||
| Bagoni et al. (121) | 2021 | Italy | retro | 2009.01-2019.12 | SLN(50) | EEC(G3) with MI >50% and non-EEC | 28% | NA | p=0.416 | NA | p=0.940 | 16% | 0.413 | |
| SLN+LAD(146) | 23.20% | NA | NA | 12% |
※The data refers to all types of recurrence.
N, number; LN, lymph node; DFS, disease-free survival; OS, overall survival; pro, prospective; retro, retrospective; SLN-A, SLN-algorithm; LAD, lymphadenectomy; EEC, endometrioid endometrial cancer; G, grade; CC, clear cell carcinoma; USC, uterine serous carcinoma; CSM, carcinosarcoma; MI, myometrial invasion; DM, deep myometrial invasion; LVSI, lympho-vascular invasion; m, months; y, year; NA, not applicable; HR, hazard ratio.